• Publications
  • Influence
Polymorphisms of HepG2/Erythrocyte Glucose-Transporter Gene: Linkage Relationships and Implications for Genetic Analysis of NIDDM
TLDR
The importance of this analysis is the finding of significant linkage disequilibrium between four polymorphic sites at the HepG2 GT locus and the lack of association with NIDDM in Blacks.
Extrapancreatic effects of sulfonylurea drugs.
TLDR
It is possible that SUs improve the primary defects in NIDDM through both pancreatic and extrapancreatic actions.
Myelofibrosis and systemic lupus erythematosus: reversal of fibrosis with high-dose corticosteroid therapy.
TLDR
Pulse therapy with methylprednisolone reversed both thrombocytopenia and myelofibrosis in a 24-year-old woman with SLE, the 3rd in which myel ofibrosis was reversed by corticosteroids.
Effects of bombesin and gastrin releasing peptide on catecholamine secretion from rat adrenal gland, in vitro.
TLDR
The data strongly suggest that bombesin or GRP plays a physiological role as one of the important regulators in catecholamine secretion in the adrenal gland.
Phase II study of recombinant human granulocyte-macrophage colony-stimulating factor in myelodysplastic syndrome and aplastic anemia.
TLDR
The results suggest that rhGM-CSF is effective for patients with MDS and AA, and a dose-dependent increase in circulating granulocyte counts, which was statistically significant in patients with AA.
Light and agonist alter vasoactive intestinal peptide binding and intracellular accumulation of adenosine 3',5'-monophosphate in the rat pineal gland.
TLDR
The results suggest that VIP is a neuromodulator of pineal function and prior treatment with an agonist on vasoactive intestinal polypeptide (VIP) binding and VIP stimulation of cAMP accumulation in the rat pineal gland.
Effects of long-term treatment with recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome.
TLDR
Observations indicate that treatment with rhGM-CSF can be of potential therapeutic benefit to patients with MDS, and the toxicity was generally well-tolerated.
Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) after chemotherapy in patients with non-Hodgkin's lymphoma; a placebo-controlled double blind phase III trial.
TLDR
It is suggested that rhGM-CSF can be safely administered to prevent neutropenia after chemotherapy in patients with non-Hodgkin's lymphoma.
...
1
2
3
4
5
...